Reata Pharmaceuticals (Reata Pharmaceuticals) ROCE % : 207.06% (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Reata Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Reata Pharmaceuticals's annualized ROCE % for the quarter that ended in Jun. 2023 was 207.06%.

Reata Pharmaceuticals ROCE % Historical Data

The historical data trend for Reata Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reata Pharmaceuticals ROCE % Chart

Reata Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-39.44

-71.56

-38.00

-34.46

-47.54

Reata Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
ROCE %	Get a 7-Day Free Trial															-41.44	-48.89	-60.37	-98.39	207.06

Reata Pharmaceuticals ROCE % Calculation

Reata Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-270.155	/	( ( (735.016 - 53.994)	+	(514.491 - 58.96) )	/ 2 )
	=	-270.155	/	( (681.022	+	455.531)	/ 2 )
	=	-270.155	/	568.2765
	=	-47.54 %

Reata Pharmaceuticals's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	803.884	/	( ( (453.582 - 54.598)	+	(502.587 - 125.093) )	/ 2 )
	=	803.884	/	( ( 398.984	+	377.494 )	/ 2 )
	=	803.884	/	388.239
	=	207.06 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

Reata Pharmaceuticals (NAS:RETA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Reata Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Reata Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Reata Pharmaceuticals (Reata Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reata Pharmaceuticals Inc (NAS:RETA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5320 Legacy Drive, Plano, TX, USA, 75024

Website

https://www.reatapharma.com

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

Executives

Steven Ryder	director	234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510
Antal Rohit Desai	director, 10 percent owner	C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Rajiv Patni	officer: EVP, Chief R&D Officer	C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Bhaskar Anand	officer: SVP, Chief Accounting Officer	5320 LEGACY DRIVE, PLANO TX 75024
Manmeet Singh Soni	officer: COO, CFO and President	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Dawn Carter Bir	officer: Chief Commercial Officer	C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Andrea Loewen	officer: SVP, Global Regulatory Affairs	C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Shamim Ruff	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Mcclellan William D. Jr.	director	C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
Michael D Wortley	officer: See Remarks	5320 LEGACY DRIVE, PLANO TX 75024
Meyer Colin John	officer: See Remarks	C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DR. SUITE 150, IRVING TX 75063
Biogen Inc.	other: See footnotes	225 BINNEY STREET, CAMBRIDGE MA 02142
Samina Khan	officer: SVP, Chief Medical Officer	5320 LEGACY DRIVE, PLANO TX 75024